{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:11:58Z","timestamp":1782817918352,"version":"3.54.5"},"reference-count":13,"publisher":"Japanese Circulation Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2020,8,7]]},"DOI":"10.1253\/circrep.cr-20-0017","type":"journal-article","created":{"date-parts":[[2020,6,19]],"date-time":"2020-06-19T22:05:34Z","timestamp":1592604334000},"page":"440-445","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and Safety of Landiolol in Patients With Ventricular Tachyarrhythmias With or Without Renal Impairment\u3000\u2015 Subanalysis of the J-Land II Study \u2015"],"prefix":"10.1253","volume":"2","author":[{"given":"Tsuyoshi","family":"Shiga","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanori","family":"Ikeda","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Toho University Faculty of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Shimizu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Kinugawa","sequence":"additional","affiliation":[{"name":"Internal Medicine (2), Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuhiro","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Nippon Medical School"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryozo","family":"Nagai","sequence":"additional","affiliation":[{"name":"Jichi Medical University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Daimon","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Hyogo College of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Oki","sequence":"additional","affiliation":[{"name":"Early Clinical Development Planning II, Ono Pharmaceutical Co. Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruka","family":"Okamoto","sequence":"additional","affiliation":[{"name":"Clinical Operation Division I, Ono Pharmaceutical Co. Ltd"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeshi","family":"Yamashita","sequence":"additional","affiliation":[{"name":"The Cardiovascular Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","unstructured":"1. Cleveland Clinic. Sudden cardiac death (sudden cardiac arrest). https:\/\/my.clevelandclinic.org\/health\/diseases\/17522-sudden-cardiac-death-sudden-cardiac-arrest (accessed June 11, 2020)."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Turakhia MP, Blankestijn PJ, Carrero JJ, Clase CM, Deo R, Herzog CA, et al. Chronic kidney disease and arrhythmias: Conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. <i>Eur Heart J<\/i> 2018; 39: 2314\u20132325.","DOI":"10.1093\/eurheartj\/ehy060"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Wan C, Herzog CA, Zareba W, Szymkiewicz SJ. Sudden cardiac arrest in hemodialysis patients with wearable cardioverter defibrillator. <i>Ann Noninvasive Electrocardiol<\/i> 2014; 19: 247\u2013257.","DOI":"10.1111\/anec.12119"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Takahashi A, Shiga T, Shoda M, Manaka T, Ejima K, Hagiwara N. Impact of renal dysfunction on appropriate therapy in implantable cardioverter defibrillator patients with non-ischaemic dilated cardiomyopathy. <i>Europace<\/i> 2009; 11: 1476\u20131482.","DOI":"10.1093\/europace\/eup210"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Myoishi M, Yasuda S, Miyazaki S, Ueno K, Morii I, Satomi K, et al. Intravenous administration of nifekalant hydrochloride for the prevention of ischemia-induced ventricular tachyarrhythmia in patients with renal failure undergoing hemodialysis. <i>Circ J<\/i> 2003; 67: 898\u2013900.","DOI":"10.1253\/circj.67.898"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Nagai R, Kinugawa K, Inoue H, Atarashi H, Seino Y, Yamashita T, et al. Urgent management of rapid heart rate in patients with atrial fibrillation\/flutter and left ventricular dysfunction: Comparison of the ultra-short-acting \u03b2<sub>1<\/sub>-selective blocker landiolol with digoxin (J-Land Study). <i>Circ J<\/i> 2013; 77: 908\u2013916.","DOI":"10.1253\/circj.CJ-12-1618"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Ikeda T, Shiga T, Shimizu W, Kinugawa K, Sakamoto A, Nagai R, et al. Efficacy and safety of the ultra-short-acting \u03b2<sub>1<\/sub>-selective blocker landiolol in patients with recurrent hemodynamically unstable ventricular tachyarrhymias: Outcomes of J-Land II study. <i>Circ J<\/i> 2019; 83: 1456\u20131462.","DOI":"10.1253\/circj.CJ-18-1361"},{"key":"8","unstructured":"8. JCS\/JHRS 2020 guideline on pharmacotherapy of cardiac arrhythmias (in Japanese). https:\/\/www.j-circ.or.jp\/cms\/wp-content\/uploads\/2020\/04\/JCS2020_Ono.pdf (accessed June 11, 2020)."},{"key":"9","unstructured":"9. Al-Khatib SM, Stevenson WG, Ackerman MJ, Bryant WJ, Callans DJ, Curtis AB, et al. 2017 AHA\/ACC\/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: A report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. <i>J Am Coll Cardiol<\/i> 2018; 72: e91\u2013e220."},{"key":"10","unstructured":"10. Shiroya T, Ichioka Y, Yoshida K, Nishijima K, Omawari N, Naka M, et al. Pharmacological studies of ONO-1101 as a betablocking agent with high beta 1 selectivity and ultra-short duration of action. <i>Kiso To Rinsho<\/i> 1997; 31: 2913\u20132923 (in Japanese)."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Kono T, Yanagiya N, Nishimura K. Successful treatment of supraventricular tachyarrhythmias with landiolol during hemodialysis in a patient after receiving cardiac surgery. <i>J Jpn Soc Intensive Care Med<\/i> 2010; 17: 77\u201378.","DOI":"10.3918\/jsicm.17.77"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kinugawa K, Nagai R, Inoue H, Atarashi H, Seino Y, Yamashita T, et al. Impacts of patient characteristics on the effectiveness of landiolol in AF\/AFL patients complicated with LV dysfunction: Subgroup analysis of the J-Land study. <i>Adv Ther<\/i> 2014; 31: 426\u2013439.","DOI":"10.1007\/s12325-014-0111-2"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Dowling TC, Briglia AE, Fink JC, Hanes DS, Light PD, Stackiewicz L, et al. Characterization of hepatic cytochrome P4503A activity in patients with end-stage renal disease. <i>Clin Pharmacol Ther<\/i> 2003; 73: 427\u2013434.","DOI":"10.1016\/S0009-9236(03)00056-0"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/2\/8\/2_CR-20-0017\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,8]],"date-time":"2020-08-08T03:24:35Z","timestamp":1596857075000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/2\/8\/2_CR-20-0017\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,7]]},"references-count":13,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-20-0017","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,7]]}}}